 |
|
vatalanib
An orally bioavailable anilinophthalazine with potential antineoplastic activity. Vatalanib binds to and inhibits the protein kinase domain of vascular endothelial growth factor receptors 1 and 2; both receptor tyrosine kinases are involved in angiogenesis. This agent also binds to and inhibits related receptor tyrosine kinases, including platelet-derived growth factor (PDGF) receptor, c-Kit, and c-Fms. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonyms: | | CGP79787D
PTK787/ZK 222584 | | | | Code names: | | CGP-79787
PTK787
ZK 222584 | | | | Chemical structure names: | | - 1-[4-Chloroanilino]-4-[4-pyridylmethyl]phthalazine Succinate
- 1-Phthalazinamine, N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-, butanedioate (1:1)
| | |
|
|
